SHR-1826 alone or with immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (SHR-1826) alone or with immunotherapy for people with advanced liver cancer that has not responded to at least one prior treatment. It aims to see if the treatment can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer that has been confirmed by a biopsy or tissue test, and it cannot be removed completely with surgery.
- You have tried at least one standard treatment for your cancer, and it either stopped working or you couldn't tolerate it.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- Your doctor expects you to live at least 12 more weeks.
- Your major organs (like heart, kidneys, liver) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a new drug, SHR-4506, for people with advanced cancers that have stopped responding to standard treatments or cannot be treated with standard options. It aims to see if the drug is safe and helpful.
This trial tests a combination of three drugs (SHR-8068, Adebrelimab, and Apatinib) given before and after surgery for liver cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Hear when a new Hepatocellular Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.